Did You Know? | Overweight and obese patients with Crohn’s disease who initiate treatment with adalimumab are more likely to have lower trough concentrations and experience treatment failure: https://t.co/tBwRJeQRIi Early optimized precision-guided dosin…
RT @amelia_kellar: High Body Mass Index and Response to Anti-Tumor Necrosis... : Official journal of the American College of Gastroenterolo…
Higher BMI z score >1 associated with greater adalimumab treatment failure and lower drug levels, in clinical trial in children with Crohn's disease https://t.co/AEcph1PdAq
High Body Mass Index and Response to Anti-Tumor Necrosis... : Official journal of the American College of Gastroenterology | ACG https://t.co/DVEycDQiJ5